Do inflammatory markers add predictive information of death beyond that provided by age and comorbidity in chronic renal failure patients?

Nephrology Dialysis Transplantation

Volumn 21, Issue 6, 2006, Pages 1575-1581

  Caravaca, Francisco S ^a   Martín, María Victoria ^a   Barroso, Sergio ^a   Ruiz, Belén ^a   Hernández Gallego, Román ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

C reactive protein; Chronic renal failure; Inflammatory markers; Mortality; White blood cell count

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATE BINDING AGENT; VITAMIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DEMOGRAPHY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PERITONEAL DIALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; COMORBIDITY; CREATININE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE;

EID: 33746012877     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl033     Document Type: Article

References (23)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in haemodialysis patients. Kidney Int 1999; 55: 648-658
2. Yeun JY, Levine RA, Mantadilov V et al. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
3. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int 2002; 61 [Suppl 80]: S103-S108
4. Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798
5. Wang AY, Woo J, Lam CW et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14: 1871-1879
6. Böger CA, Götz A, Stubanus M et al. C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney Int 2005; 68: 217-227
7. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337
8. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772
9. Rao M, Guo D, Perianayagam MC, Tighiouart H et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45: 324-333
10. Reddan DN, Klassen PS, Szczech LA et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1167-1173
11. Johnson DW, Wiggins KJ, Armstrong KA, Campbell SB, Isbel NM, Hawley CM. Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. Kidney Int 2005; 67: 738-743
12. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Sem Dial 2002; 15: 329-337
13. Wanner C, Metzger T. C-reactive protein a marker for all cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17 [Suppl 8]: 29-32
14. Peppys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111: 1805-1812
15. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1507-1519
16. van Manen JG, Korevaar JG, Dekker FW, Boeschoten EW, Bossuyt PMM, Krediet RT, for the NECOSAD Study Group. How to adjust for comorbidity in survival studies in ESRD patients: A comparison of different indices. Am J Kidney Dis 2002; 40: 82-89
17. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
18. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney Int 2002; 61: 615-620
19. Tsirpanlis G, Bagos P, Ioannou D et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 150-157
20. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557
21. Kim SB, Min WK, Lee SK, Park JS, Hong CD, Yang WS. Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2002; 39: 342-346
22. Friedman AN, Hunsicker LG, Selhub J, Bostom AG, and the Collaborative Study Group. C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005; 68: 773-778
23. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004; 15: 2916-2922